MTOR and cancer: Oestrogen may act through the PI3K - protein kinase B (PKB, also known as AKT) - mammalian target of rapamycin (mTOR) pathway to induce NRF2 accumulation [59, 61], supporting the emerging clinical strategy of treating BRCA1-related cancers with PI3K inhibitors.